NeoGenomics (NEO) Q2 2026 earnings review
Pricing Power Pivots Profitability, But Operating Losses Remain
NeoGenomics is successfully executing its strategic pivot: sacrificing low-margin volume to drive high-margin Average Unit Price (AUP). Clinical revenue surged 14% on the back of 26% NGS growth, driving AUP to $515 (+12% YoY) while volume growth slowed to 1.9%. This mix shift generated a record $20M in operating cash flow and drove a guidance raise. However, the headline GAAP Net Income of $2.2M is a mirage fueled by an $11.2M gain on debt extinguishment—the core business still operates at a $9.8M loss.
🐂 Bull Case
The focus on high-value NGS testing is structurally improving margins. Adjusted Gross Profit Margin expanded 260 bps YoY to 48.1%, and Adjusted EBITDA jumped 36% to $14M.
The company generated $20M in operating cash flow in Q2 (reversing a $8.1M burn in Q1), completely alleviating near-term liquidity concerns and funding a $25M stock buyback.
🐻 Bear Case
Despite the margin expansion, the company posted a $9.8M operating loss. The positive net income was entirely manufactured by financial engineering (debt extinguishment gain).
Clinical test volume grew just 1.9% YoY. While intentional as the company sheds low-value contracts, relying exclusively on AUP expansion to drive top-line growth leaves zero margin for execution error.
⚖️ Verdict: 🟢
Bullish. The strategic thesis is working flawlessly. Management promised they would drop low-margin tests to drive AUP, expand gross margins, and generate cash. Q2 delivered on all three fronts, justifying the guidance raise.
Key Themes
AUP Accelerating on NGS Mix Shift
The shift toward Next-Generation Sequencing (NGS) continues to be the primary engine of value creation. NGS revenue grew 26% YoY, fundamentally changing the unit economics of the business. Average Unit Price (AUP) jumped 12% to $515, a significant acceleration from the 8% growth seen in Q1.
Product Pipeline: RaDaR ST Indication Expansion
NeoGenomics submitted new evidence to MolDx supporting Medicare reimbursement for a third indication of its RaDaR ST assay. Expanding the reimbursable label for RaDaR ST is critical to capturing a larger share of the $20B Minimal Residual Disease (MRD) market and sustaining AUP growth.
Cash Flow Generation Reversing
Operating cash flow saw a massive sequential reversal, generating $20M in Q2 compared to an $8.1M burn in Q1. This cash generation allowed the company to comfortably manage a major debt refinancing while keeping $146M on the balance sheet.
Earnings Quality: Operating Loss Masked by Debt Gain
Management headline highlights GAAP Net Income of $2M, a sharp reversal from the $45M loss a year ago. However, this contradicts the actual operating narrative: $11.2M of this came from a one-time gain on debt extinguishment. Loss from operations was still $9.8M. The core business is not yet GAAP profitable.
Non-Clinical (Pharma) Segment Remains a Drag
While Clinical revenue grew 14%, total consolidated revenue grew only 11%. This arithmetic confirms that the Non-Clinical (pharma services) business remains a significant headwind, reflecting ongoing macroeconomic budget pressures across the biotech and pharma landscape.
Clinical Volume Growth Decelerating
Clinical volume grew just 1.9% YoY (363,498 vs 356,630 tests). While shedding low-value contracts is the stated strategy, growth has precipitously dropped from 15% in Q3 2025 down to under 2%. The company will soon need to prove it can grow volume organically in its high-value segments once the low-value culling is complete.
DOJ Settlement Finalized
The company finalized a civil settlement with the Department of Justice regarding a self-disclosed matter concerning consulting services. While resolving the investigation removes a legal overhang, it underscores past compliance risks that required remediation.
Other KPIs
Accelerating significantly. Grew 36% YoY from $11M in Q2 2025. This proves the strategy of sacrificing low-margin volume for high-margin NGS tests directly trickles down to core profitability.
Down 19% YoY. The decrease was primarily due to the absence of a $20M impairment charge taken in the prior year period. Excluding that charge, baseline operating expenses are effectively flat, showing strong cost discipline while revenue grew 11%.
The company aggressively optimized its balance sheet by issuing $316M in 0.75% convertible senior notes due 2032. Proceeds were used to retire $276M of existing 0.25% notes due 2028 and fund a $25M stock repurchase. This extends their maturity runway significantly.
Guidance
Accelerating. Raised from the prior guide of $797 - $803 million. At the midpoint ($804M), this represents 10.5% YoY growth over FY25's $727 million.
Accelerating. Raised from prior guide of $55 - $57 million. The midpoint of $57M implies 32.5% YoY growth compared to FY25's $43 million, heavily outpacing revenue growth and demonstrating immense operating leverage.
Improving. The loss projection narrowed considerably from the prior range of $(63) - $(50) million. Much of this improvement is mathematically driven by the Q2 $11.2M gain on debt extinguishment, but core operational efficiency is also contributing.
Key Questions
Volume Floor
With clinical test volume growth decelerating to 1.9% as you shed low-value contracts, when do we fully lap these exits and establish a new baseline for organic volume growth?
MolDx Timeline for RaDaR ST
You've submitted evidence for a third indication to MolDx for RaDaR ST. What is your expectation for the timeline on a coverage decision, and how much of this new indication is baked into the updated FY26 guidance?
Pharma Segment Trajectory
Given the wide gap between total revenue growth (11%) and clinical growth (14%), the non-clinical business clearly remains pressured. Have we found a bottom in the pharma services segment, or should we expect further deterioration in H2?